Skip to main content
SpringerLink
Log in

Exemestane is a useful second-line agent for hormone-sensitive advanced breast cancer

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Njar VCO, Brodie AMH. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999 Aug; 58(2): 233–55

    Article  PubMed  CAS  Google Scholar 

  2. Wiseman LR, Adkins, JC. Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998 Oct; 13(4): 321–32

    Article  PubMed  CAS  Google Scholar 

  3. Lamb HM, Adkins, JC. Letrozole: a review of its use in post-menopausal women with advanced breast cancer. Drugs 1998 Dec; 56(6): 1125–40

    Article  PubMed  CAS  Google Scholar 

  4. Wiseman LR, Goa KL. Formestane: a review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer. Drugs Aging 1996; 9(4): 292–306

    Article  PubMed  CAS  Google Scholar 

  5. Scott LJ, Wiseman LR. Exemestane. Drugs 1999 Oct; 58(4): 675–80

    Article  PubMed  CAS  Google Scholar 

  6. British National Formulary No. 38. London: The Pharmaceutical Press, 1999 Sep: 394-6

  7. 1999 Drug Topics® Red Book®. NJ: Medical Economics Company, Inc., 1999

  8. Kaufmann M, Bajetta E, Dirix LY et al. Survival advantage of exemestane (EXE, Aromasin® over megestrol acetate in postmenopausal women with advanced breast cancer refractory to tamoxifen: results of a phase III randomised double-blind study [abstract No. 412]. Proc Am Soc Clin Oncol 1999; 18: 109a

    Google Scholar 

  9. Miller WR. Exemestane: a viewpoint. Drugs 1999 Oct; 58(4): 681–2

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Exemestane is a useful second-line agent for hormone-sensitive advanced breast cancer. Drugs Ther. Perspect 15, 1–4 (2000). https://doi.org/10.2165/00042310-200015070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200015070-00001

Keywords

Search

Navigation